middle-of-the-night awakening

middle-of-the-night awakening

Insomnia characterised by a difficulty in returning to sleep once awakened after going to sleep for the night and before getting up at one’s usual time in the morning. MOTN awakening is associated with excessive daytime sleepiness and fatigue.

Frequency
Occurs in one-third of the general population at least three nights/week.

Aetiology
Anxiety, obstructive sleep apnoea, chronic pain, pregnancy, toilet needs, depression, bipolar disorder, obesity, hypertension, heart disease, alcohol consumption, menopause, etc.

Management
No medication is consistently effective.
Mentioned in ?
References in periodicals archive ?
The US Food Drug Administration (FDA) had reportedly approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
On 23 November 2011, the FDA approved Intermezzo sublingual tablet C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty in returning to sleep.
A review of store shelves showed her that there were no products available to address middle-of-the-night awakening, the sleep problem she shares with an estimated 70 million Americans.
This delivery approach is designed to treat people who have difficulty maintaining sleep after falling asleep naturally, both allowing natural sleep induction and preventing middle-of-the-night awakening without residual effects.
For the 15 and 20 mg doses, there was a significant reduction in the number of middle-of-the-night awakenings during hours 3-7 of the 8-hour sleep period (NAASO3-7) as well as increased total sleep time for hours 3-7 (TST 3-7)," said study investigator Russell Rosenberg, Ph.
According to the company, the US Food Drug Administration (FDA) had approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
24 November 2011 - US Transcept Pharmaceuticals Inc (NASDAQ:TSPT) said on Wednesday the US Food and Drug Administration (FDA) had approved Intermezzo (zolpidem tartrate sublingual tablet) C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Pharmaceutical company Transcept Pharmaceuticals Inc (Nasdaq:TSPT) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for Intermezzo C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
It is designed to treat people who have difficulty maintaining sleep after falling asleep naturally by preventing middle-of-the-night awakening while avoiding residual effects.
The formulation is designed to treat people who have difficulty maintaining sleep but not falling asleep by preventing middle-of-the-night awakening while avoiding residual effects.
The recommended doses of Intermezzo[R], a lower-dose zolpidem product approved for middle-of-the-night awakenings, has not changed.
Has the shortest [Sonata] half-life of the three nonbenzodiazepine BRAs, so it may be used for middle-of-the-night awakenings.